Inhibitory effects of the combination of HER-2 antisense oligonucleotide and chemotherapeutic agents used for the treatment of human breast cancer

Cancer Gene Therapy

Volumn 8, Issue 10, 2001, Pages 728-739

  Rait, Antonina S ^a   Pirollo, Kathleen F ^a   Rait, Vladimir ^a   Krygier, Jeffrey E ^a   Xiang, Laiman ^a   Chang, Esther H ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

Antisense oligonucleotide; Breast cancer cell lines; Chemosensitization; Combination therapy; Drug sensitivity; HER 2 neu (c erbB 2)

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CISPLATIN; DOXORUBICIN; FLUOROURACIL; GENE PRODUCT; PACLITAXEL; PHOSPHOROTHIOATE ANTISENSE OLIGONUCLEOTIDE; UNCLASSIFIED DRUG; VINBLASTINE SULFATE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DRUG POTENTIATION; FIBROBLAST; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; ONCOGENE NEU; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL DIVISION; DRUG THERAPY, COMBINATION; FEMALE; FIBROBLASTS; FLOW CYTOMETRY; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, ERBB-2; TUMOR CELLS, CULTURED;

EID: 0034780459     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700359     Document Type: Article

References (42)

1. The neu-oncogene: Signal transduction pathways, transformation mechanisms and evolving therapies
2. The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: From orphanhood to multiple stromal ligands
3. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors
4. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors
5. Amplification of a novel v-erbB-related gene in a human mammary carcinoma
6. Heterogeneous expression of erbB-2 messenger RNA in human breast cancer
7. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
8. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
9. Over-expression of the EGF receptor-related proto-oncogene erbB2 in human mammary tumor cell lines by different molecular mechanisms
10. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading
11. Sporadic amplification of the HER2/neu protooncogene in adenocarcinomas of various tissues
12. Molecular and clinical aspects of the Neu/ErbB-2 receptor tyrosine kinase
13. Over-expression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms
14. The HER-2/neu oncogene: Prognostic factor, predictive factor and target for therapy
15. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs
16. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
17. Evidence supporting a signal transduction pathway leading to the radiation-resistant phenotype in human tumor cells
18. Sensitization of breast cancer cells to taxol by antisense HER-2 oligonucleotides
19. ErbB-2 (HER2/neu) gene copy number, p185HER-2 overexpression, and intratumor heterogeneity in human breast cancer
20. p66Shc isoform down-regulated and not required for HER-2/neu signaling pathway in human breast cancer cell lines with HER-2/neu overexpression
21. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides
22. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines
23. erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification
24. Inhibition of erbB-2-positive breast cancer cell growth by erbB-2 antisense oligonucleotides
25. Specific inhibition of breast cancer cells by antisense poly-DNP-oligoribonucleotides and targeted apoptosis
26. Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix
27. Breast tumor cell lines from pleural effusions
28. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis
29. Apoptosis by death factor
30. Bcl-2 family proteins
31. Taxol induces intemucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells
32. Antisense DNA downregulation of the ERBB2 oncogene measured by a flow cytometric assay
33. Inhibition of the erbB-2 tyrosine kinase receptor in breast cancer cells by phosphoromonothioate and phosphorodithioate antisense oligonucleotides
34. Reduction of erbB-2 gene product in mamma carcinoma cell lines by erbB-2 mRNA-specific and tyrosine kinase consensus phosphorothioate antisense oligonucleotides
35. SupraMolecular BioVectors (SMBV) improve antisense inhibition of erbB-2 expression
36. Antisense oligonucleotides specific for the HER2/neu oncogene inhibit the growth of human breast carcinoma cells that overexpress HER2/neu
37. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells
38. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization
39. A gain-of-function mutation in Drosophila MAP kinase activates multiple receptor tyrosine kinase signaling pathways
40. A temperature-sensitive MEK mutation demonstrates the conservation of the signaling pathways activated by receptor tyrosine kinases
41. Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines